Lantheus Announces Acquisition of Cerveau Technologies, Expanding Imaging Pipeline into Alzheimer’s Disease

MK-6240 is an F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s Disease

Lantheus Holdings, a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it has acquired Knoxville-based Cerveau Technologies, Inc. (“Cerveau”). Cerveau’s asset is MK-6240, a second-generation F 18-labeled positron emission tomography (“PET”) imaging agent that targets Tau tangles in Alzheimer’s disease.

Recent AiThority News : Taboola Beta Tests Integration of Generative AI, Including ChatGPT, to Revolutionize Ad Creation for Advertisers

Alzheimer’s disease is a degenerative neurological disorder that causes an inexorable decline in cognition and function. In the U.S., there are an estimated 6.5 million people living with Alzheimer’s disease. As the population ages, it is likely that the prevalence of this disease will continue to rise and, by 2050, the number of people 65 and older with Alzheimer’s disease may grow to 12.7 million.ⁱ

MK-6240 is a clinical stage PET development candidate designed to detect Tau protein in the form of neurofibrillary tangles in the brains of patients with known or suspected Alzheimer’s disease. MK-6240 has the potential to aid in diagnosing, staging, and informing treatment selection and response to therapy for Alzheimer’s disease. Although in clinical development, MK-6240 is currently being used in more than 60 academic and industry clinical trials around the world for several late-stage Alzheimer’s disease therapeutic candidates being developed by more than 16 pharmaceutical companies.

“This exciting acquisition aligns with our growth strategy, further diversifying our radiopharmaceutical diagnostic imaging agent pipeline to now include the most widely-used Tau PET imaging agent in Alzheimer’s disease and will provide us with an extensive roster of academic collaborations and pharmaceutical partnerships,” said Etienne Montagut, Lantheus Chief Business Officer.

Under the terms of the agreement, Lantheus will pay an upfront payment and potential additional development and commercial milestone payments. Additionally, Lantheus will pay double-digit royalty payments for research revenue and commercial sales. Structured as a stock purchase, the agreement specifies, among other things, that the seller will also provide transition and clinical development services for a prescribed time following the closing of the transaction.

“I am pleased to be part of the next phase in the evolution of one of the most utilized research technologies available to support the development of therapeutics in Alzheimer’s research. We are excited at the potential to utilize MK-6240 as a key clinical tool supporting patient care as more therapeutics become available to the healthcare community,” said Rick Hiatt, Cerveau Chief Executive Officer. “With Lantheus’ expertise in radiopharmaceutical diagnostics and ability to scale operations as volume continues to accelerate, there is no doubt that Lantheus is the ideal company to advance research collaborations and patient access towards bringing this leading-edge precision imaging tracer to patients.”

NLP News: Fast Track Unleashes the Power of AI-Language Technology for Automated Campaign Generation

Chestnut Partners, Inc. acted as exclusive financial advisor to Cerveau in this transaction. Foley Hoag LLP acted as legal advisor to Lantheus in connection with the transaction.

With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden.

Cerveau’s vision is to be the premier provider of information and technology to researchers and clinicians in order to improve brain health

 Latest Aithority Insights : Squashing Long Wait Time & Call Friction: AI’s Role in Transforming Contact Centers

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Lantheus Announces Acquisition of Cerveau Technologies, Expanding Imaging Pipeline into Alzheimer’s Disease appeared first on AiThority.

diagnostics
therapeutics
healthcare
artificial intelligence
ai
pharmaceutical